Physician profile
Volkan Sumer
NPI 1730185125
$3,353.94
in general payments reported to CMS, 2019-2025
35 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $524 · 2021: $496 · 2022: $144 · 2023: $171 · 2024: $438 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.39 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $613.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $313.97 | 2019-2025 | Veozah |
| Novo Nordisk INC | $243.25 | 2019-2025 | Ozempic, Wegovy |
| Abbvie INC. | $208.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $199.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $193.21 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $184.31 | 2019-2020 | |
| Abbott Laboratories | $179.10 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.57 | 2019-2025 | Jardiance |
| Amgen INC. | $140.20 | 2019-2025 | Evenity, Repatha, Otezla |
| Allergan, INC. | $130.60 | 2020 | |
| Dexcom, INC. | $109.01 | 2021-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $61.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $55.07 | 2019 | |
| Sumitomo Pharma America, INC. | $54.17 | 2024-2025 | Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.80 | 2019-2020 | |
| Pacira Therapeutics, INC. | $45.01 | 2019 | |
| Lilly USA, LLC | $40.31 | 2020-2025 | Kisunla |
| Orthogenrx INC. | $38.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.25 | 2019-2025 | Camzyos |
| Scpharmaceuticals INC. | $30.83 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $27.39 | 2024 | |
| Exact Sciences Corporation | $25.33 | 2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $25.26 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.69 | 2025 | Rexulti |
| Avanos Medical | $20.40 | 2025 | Genvisc 850 Sodium Hyaluronate |
| Paratek Pharmaceuticals, INC. | $19.38 | 2025 | Xhance, Nuzyra |
| Inspire Medical Systems, INC. | $18.79 | 2024 | Inspire |
| Phathom Pharmaceuticals, INC. | $17.21 | 2025 | Voquezna |
| Insulet Corporation | $17.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.57 | 2020 | |
| Medtronic, INC. | $16.45 | 2023 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $16.41 | 2024 | Nexletol |
| Philips North America LLC | $14.69 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Volkan Sumer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.